A delayed diagnosis can cause a progression in severity (from mild to moderate to severe), increased suffering for the entire family, as well as enhance the risk of long-term neurological damage and the time it takes for them to heal. The post The Hidden Autoimmune Disorder Affecting Our Kids: Understanding PANS and PANDAS appeared first…
This brief evaluates what is currently known about fraud and abuse in the Affordable Car Act (ACA) Marketplace, including how the final Marketplace Integrity and Affordability Rule and proposed budget reconciliation legislation would change existing Marketplace enrollment and eligibility standards.
In the early days of the West Texas measles outbreak, Thang Nguyen eyed the rising number of cases and worried. His 4-year-old son was at risk because he had received only the first of the vaccine’s two doses. So, in mid-March, he took his family to a primary care clinic at the University of Texas…
CLARKESVILLE, Ga. — Last September, Alton Fry went to the doctor concerned he had high blood pressure. The trip would result in a prostate cancer diagnosis. So began the stress of trying to pay for tens of thousands of dollars in treatment — without health insurance. “I’ve never been sick in my life, so I’ve…
Some hospitals are turning to AI to help manage declining revenue and financial pressure, but one expert says success depends on more than just buying new tech. Prashant Karamchandani of Chartis urged health systems to pair AI adoption with foundational work like change management, continuous improvement and operating model redesign. The post Why Hospitals Must…
Employers are advocating for changes to the 340B Drug Pricing Program, arguing that it allows hospitals to “buy low and sell high” by purchasing discounted medications and charging insured patients full price. The post Why Employers Think the 340B Program Needs Reform appeared first on MedCity News.
Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema. The post BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal appeared first on MedCity News.
Through the convergence of proactive policy, advanced technology and strategic public-private partnerships, we can achieve this “no wrong door” vision and deliver a connected, streamlined social safety net that’s more efficient, economical, and effective. Here’s how. The post No Wrong Door: How Policy, Technology & Partnerships Can Power a Connected Social Safety Net appeared first…
Public debate is growing, but the real path forward lies in defining autism’s biology — and for the first time, we can. The post The Administration’s Autism Plan Is Controversial – But It Also Presents a Vital Opportunity appeared first on MedCity News.
When we talk about post-traumatic stress disorder (PTSD), a condition fundamentally born from overwhelming experiences that leave a long-term imprint on the body, our mainstream approach often feels stuck in the past. The post The $232 Billion Problem: The Price of Overlooking the Impact of Trauma in the U.S. appeared first on MedCity News.